Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)
Launched by GLAXO WELLCOME · Aug 30, 2001
Trial Information
Current as of March 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Patient must have AIDS related complex (ARC) as defined by Walter Reed stages, be ambulatory, and be able to give informed consent.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with unstable disease characterized by the following are excluded:
- • Hospitalization within the past 14 days.
- • Major opportunistic infection, current or past.
- * An active infection of onset during the past 30 days, as evidenced by symptoms, signs, or laboratory abnormalities such as:
- • Temperature = or \> 100.5 degrees F.
- • Night sweats.
- • Weight loss = or \> 10 percent of body weight.
- • Diarrhea (3 or more bowel movements/day).
- • Persistent cough, shortness of breath, or dyspnea on exercise.
- • Abnormal chest x-ray suggesting pneumonia or increased arterial-alveolar (A-a) gradient.
- • Altered mental status, seizures, or focal neurologic signs.
- • Abnormal computerized tomography (CT) scan or magnetic resonance imaging (MRI) suggestive of toxoplasmosis, peripheral mononuclear leukocytes, lymphoma, or other focal abnormality of the central nervous system (CNS).
- • Abnormal cerebrospinal fluid (CSF) suggestive of cryptococcal, mycobacterial, or other meningitis. (The decision to perform invasive tests, such as lumbar puncture, specialized microbiological tests such as bone marrow culture for Mycobacteria or Histoplasma capsulatum, or specialized radiological tests such as CT scan or MRI should be based on clinical assessment of the patient.)
- • Kaposi's sarcoma.
- • Lymphoma; malignancy requiring chemotherapy.
- • Dementia.
- • Requiring hemodialysis or renal insufficiency or failure.
- • Leukopenia.
- • Thrombocytopenia.
- Patients with the following are excluded:
- • Unstable disease.
- • Kaposi's sarcoma.
- • Lymphoma; malignancy requiring chemotherapy.
- • Dementia.
- • Major opportunistic infection, current or past.
- • Anemia (hemoglobin less than 9.5 g/dl).
- Prior Medication:
- Excluded within 1 month of study entry:
- • Ribavirin or zidovudine (AZT) or other antivirals.
- • Immunomodulating agents.
About Glaxo Wellcome
Glaxo Wellcome, a leading global biopharmaceutical company, is dedicated to advancing healthcare through innovative research and development of new therapies. With a strong focus on addressing unmet medical needs, Glaxo Wellcome combines scientific excellence with a commitment to improving patient outcomes across various therapeutic areas, including respiratory, infectious diseases, and oncology. The company is recognized for its robust clinical trial portfolio, leveraging cutting-edge technology and collaborative partnerships to drive the development of transformative treatments. Glaxo Wellcome upholds the highest ethical standards in clinical research, ensuring patient safety and integrity throughout the trial process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Houston, Texas, United States
Washington, District Of Columbia, United States
Washington, District Of Columbia, United States
Los Angeles, California, United States
Miami, Florida, United States
New York, New York, United States
Durham, North Carolina, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials